Search
mephenytoin; methoin; methylphenylethylhydantoin (Mesantoin)
Tradename: Mesantoin.
Indications:
1) tonic-clonic seizures
2) partial seizures
3) partial seizures with motor symptoms
4) partial complex seizures refractory to other agents
5) (see phenytoin)
Dosage:
1) 100 mg PO BID/TID/QID [1]
2) start 50-100 mg QD [2]
3) increase 50-100 mg at weekly intervals
4) do NOT increased dose more frequently than weekly
5) average dose 200-600 mg/day
Tabs: 100 mg.
Adverse effects:
1) common (> 10%)
- psychiatric changes, slurred speech, trembling, constipation, nausea/vomiting, dizziness, drowsiness
2) less common (1-10%)
- anorexia, weight loss, rash, headache, insomnia, leukopenia, hepatitis, increase in serum creatinine
3) uncommon (< 1%)
- Stevens-Johnson syndrome or SLE-like syndrome, paresthesia, gingival hyperplasia, hypotension, bradycardia, cardiac arrhythmias, cardiovascular collapse, confusion, peripheral neuropathy, fever, ataxia, blood dyscrasia, thrombophlebitis, diplopia, nystagmus, blurred vision, lymphadenopathy, Hodgkin's disease-like syndrome, serum sickness, photophobia
4) other (see phenytoin)
Drug interactions: (see phenytoin)
Laboratory:
- mephenytoin in serum/plasma
Interactions
drug interactions
drug adverse effects of anticonvulsants
monitor with anticonvulsants
Related
phenytoin; diphenylhydantoin; PTN (Dilantin, Dephenylan, Antilepsin)
General
anticonvulsant
hydantoin; glycolylurea
Properties
MISC-INFO: elimination route LIVER
pregnancy-category C
safety in lactation ?
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998 - not on National VA formulary
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998